Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis

References

• Cremer B, Sandmaier BM, Bethge W, et al. Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective. Onkologie. 2011;34(12):710–715.
   PubMedGoogle Scholar
• Fadilah SAW, Aqilah P. Promising Role of Reduced-Toxicity Hematopoietic Stem Cell Transplantation (PART-I). Stem Cell Rev Rep. 2012;8(4):1254–1264.
   PubMed Web of Science ®Google Scholar
• Valcárcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26(4):577–584.
   PubMed Web of Science ®Google Scholar
• Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Transplantation. 2006;108(3):836–846.
   Google Scholar
• Blaise D, Castagna L. Do different conditioning regimens really make a difference? Hematology Am Soc Hematol Educ Program. 2012;2012(1):237–245.
   PubMedGoogle Scholar
• Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344–353.
   PubMed Web of Science ®Google Scholar
• Sanz J, Boluda JCH, Martín C, Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant. 2012;47(10):1287–1293.
   PubMed Web of Science ®Google Scholar
• Esquirol A, Pascual MJ, Ortiz M, et al. Single-Agent GvHD prophylaxis with tacrolimus after post-Transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. Bone Marrow Transplant. 2017;52(9):1273–1279.
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning. Biol Blood Marrow Transplant. 2013;19(1):117–122.
   PubMed Web of Science ®Google Scholar
• Arcese W, Picardi A, Santarone S, on behalf of Rome Transplant Network, et al. Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: An update. Bone Marrow Transplant. 2015;50(S2):S24–S30.
   PubMedGoogle Scholar
• El-Cheikh J, Massoud R, Moukalled N, et al. Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation. Clin Lymphoma, Myeloma Leuk. 2018;18(5):368–374.
   PubMed Web of Science ®Google Scholar
• Saraceni F, Labopin M, Hamladji R-M, Acute Leukemia Working Party of the European society for Blood and Marrow Transplantation (EBMT), et al. Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget. 2018;9(3):3379–3393.
   PubMedGoogle Scholar
• Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372–1377.
   PubMed Web of Science ®Google Scholar
• Snyder DS, Palmer J, Gaal K, et al. Improved Outcomes Using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant. 2010;16(2):281–286.
   PubMed Web of Science ®Google Scholar
• Wang L, Gu Z, Zhai R, et al. The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Transfusion. 2015;55(9):2134–2141.
   PubMed Web of Science ®Google Scholar
• Ho VT, Aldridge J, Kim HT, et al. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(7):844–850. Comparison
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19(56):6680–6686.
   PubMed Web of Science ®Google Scholar
• Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. JCO. 2008;26(35):5767–5774.
   PubMed Web of Science ®Google Scholar
• Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112(12):4425–4431.
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115(5):1098–1105.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Palmer JM, O'Donnell MR, et al. Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. Leuk Res. 2012;36(9):1152–1156.
   PubMed Web of Science ®Google Scholar
• Perez-Simón JA, Martino R, Parody R, et al. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica. 2013;98(4):526–532.
   PubMed Web of Science ®Google Scholar
• Alyea EP, Li S, Kim HT, et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(8):920–926.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Sainvil MM, et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016;173(1):96–104.
   PubMed Web of Science ®Google Scholar
• Kornblit B, Maloney DG, Storer BE, et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica. 2014;99(10):1624–1631.
   PubMed Web of Science ®Google Scholar
• Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, et al. A Time-to-Event Model for acute kidney injury after reduced-intensity conditioning stem cell transplantation using a tacrolimus- and sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2017;23(7):1177–1185.
   PubMed Web of Science ®Google Scholar
• Guglieri-Lopez B, Perez-Pitarch A, Garcia-Cadenas I, et al. Effect of sirolimus exposure on the need for preemptive antiviral therapy for cytomeglovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1022–1030.
   Google Scholar
• Copelan E, Casper JT, Carter SL, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007;13(12):1469–1476.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295–304.
   Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim L, Logan B, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671.
   PubMed Web of Science ®Google Scholar
• Ruutu T, Barosi G, Benjamin RJ, on an initiative of the European Group for Blood and Marrow Transplantation and the European LeukemiaNet, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: Results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95–100.
   PubMed Web of Science ®Google Scholar
• Carreras E, Grañena A, Rozman C. Hepatic veno-occlusive disease after bone marrow transplant. Blood Rev. 1993;7(1):43–51.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• Ali H, Palmer J, Eroglu Z, et al. Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant. 2015;50(2):307–309.
   PubMed Web of Science ®Google Scholar
• Al-Kadhimi Z, Gul Z, Rodriguez R, et al. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1734–1744.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633.
   PubMed Web of Science ®Google Scholar
• Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2009;15(3):367–369.
   PubMed Web of Science ®Google Scholar
• Martino R, Pérez-Simón JA, Moreno E, et al. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. Biol Blood Marrow Transplant. 2005;11(6):437–447.
   PubMed Web of Science ®Google Scholar